Regen Biopharma, Inc. income statement RGBP

Annual Quarterly

In fiscal 2025, which ended Sep 30, 2025, Regen Biopharma, Inc. reported revenue of $236,561, about flat from the year before. It recorded a net loss of $1.3 million. The operating loss came to $338,540, an operating margin of -143.1%. Diluted earnings per share were -$0.05. Over the twelve months ended Jun 30, 2026, revenue was $236,560. Across the 10 fiscal years shown, revenue grew from $100,000 in fiscal 2016 to $236,561 in fiscal 2025, about 10.0% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Sep 30, 2025	FY 2024 Sep 30, 2024	FY 2023 Sep 30, 2023	FY 2022 Sep 30, 2022	FY 2021 Sep 30, 2021	FY 2020 Sep 30, 2020	FY 2019 Sep 30, 2019	FY 2018 Sep 30, 2018	FY 2017 Sep 30, 2017	FY 2016 Sep 30, 2016
Revenue	0 -0.0%	0 +0.0%	0 +86.9%	0 +0.8%	0 +105.1%	0 -44.4%	0 +0.0%	0 +10.0%	0 -9.1%	0 +10.0%	0
Research and development	0	0 -92.4%	0 -27.6%	0 +34.2%	0 +330.8%	0 +176.3%	0 -70.9%	0 -87.8%	0 -67.4%	1 +71.3%	1 +2711.8%
Selling, general and administrative	0 +279.1%	0 +27.5%	0 +31.0%	0 +60.3%	0 -76.5%	0 -52.1%	0 -50.1%	1 -32.7%	1 -9.5%	1 -50.6%	2 +217.7%
Operating income	-1 -167.2%	-0 +18.9%	-0 +39.3%	-1 -102.3%	-0 -69.2%	-0 +4.1%	-0 +72.3%	-1 +46.9%	-1 +43.2%	-3 +15.1%	-3 -318.6%
Pretax income	-1	-1 -90.7%	-1	—	—	—	—	—	—	—	—
Income tax	—	0	—	—	—	—	—	—	—	—	—
Net income	—	-1 -90.7%	-1 -157.8%	1 -52.7%	2 +136.1%	-7 -298.1%	3 +230.2%	-3 +44.4%	-5 +19.2%	-6 +24.7%	-8
Basic EPS	—	-0.05 +68.8%	-0.16 -155.2%	0.29	—	—	—	—	—	—	—
Diluted EPS	—	-0.05 +68.8%	-0.16 -155.2%	0.29	—	—	—	—	—	—	—
Weighted average shares, basic	231 +1312.3%	24 +472.3%	4 +16.2%	4 +12.8%	3 -99.9%	3,012 +113.6%	1,410 -31.9%	2,071 +1261.8%	152 +7.5%	141 +10.6%	128 +147.1%
Weighted average shares, diluted	231 +1312.3%	24 +472.3%	4 +16.2%	4	—	—	—	—	—	—	—
Other measures
Interest coverage	-4.72x	-2.14x	-5.76x	—	—	—	—	—	—	—	—
Margins
Operating margin	-339.81%	-143.11%	-176.37%	-542.79%	-270.56%	-328.09%	-190.29%	-687.99%	-1,425.78%	-2,282.62%	-2,956.96%
Pretax margin	-501.43%	-538.76%	-282.49%	—	—	—	—	—	—	—	—
Profit margin	—	-538.76%	-282.49%	913.80%	1,946.77%	-11,055.39%	3,104.02%	-2,384.71%	-4,715.20%	-5,308.22%	-7,750.59%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: RGBP (OTC), RGBPP (OTC)
Fiscal year ends: September 30
Incorporated in: NV
Headquarters: La Mesa, CA
SEC filer status: , Emerging growth company
SEC CIK: 1589150

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.